Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Moclobemide→

Moclobemide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
71320-77-9
Molecular formula
C13H17ClN2O2
Molecular weight
268.739 g/mol
Drug class
Reversible inhibitor of monoamine oxidase A (RIMA)antidepressant
Mechanism of action
Reversibly and selectively inhibits monoamine oxidase type A, reducing metabolism of noradrenaline, serotonin and dopamine and increasing their extracellular availability in the central nervous system.
Indications / reported uses
  • Treatment of depressive episodes in adults under the applicable product information; local authorisation and precautions for use with serotonergic medicines must be checked

Sources: UK SmPC — Moclobemide 150 mg tablets · UK SmPC — Moclobemide 300 mg tablets · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Reversible inhibitor of monoamine oxidase A (RIMA); antidepressant

Mechanism of action

Reversibly and selectively inhibits monoamine oxidase type A, reducing metabolism of noradrenaline, serotonin and dopamine and increasing their extracellular availability in the central nervous system.

General use cases

  • Treatment of depressive episodes in adults under the applicable product information; local authorisation and precautions for use with serotonergic medicines must be checked

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Moclobemide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Moclobemide Permitted Daily Exposure (PDE) report (the Moclobemide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Moclobemide Occupational Exposure Limit (OEL) report (the Moclobemide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.